학술논문
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study.
Document Type
journal article
Author
Source
Annals of the Rheumatic Diseases; Jun2018, Vol. 77 Issue 6, p914-921, 8p, 1 Diagram, 2 Charts, 3 Graphs
Subject
Language
ISSN
00034967
Abstract
Copyright of Annals of the Rheumatic Diseases is the property of BMJ Publishing Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)